Revvity Reports Q3 Growth and Raises 2026 Guidance

Revvity reported third-quarter 2026 revenue of $729 million and GAAP EPS from continuing operations of $0.56, while pro forma revenue was $710 million, up 7%, and pro forma adjusted EPS was $1.37. The company raised full-year 2026 guidance to approximately $2.86 billion in pro forma revenue, 5% pro forma organic growth and $5.40-$5.45 in pro forma adjusted EPS. Revvity also said its July 31, 2026 agreement to sell substantially all China Immunodiagnostics assets to an unspecified buyer for up to $200 million remains probable to close by the end of 2027, subject to adjustments, regulatory approvals and other conditions.